Pharmacogenetic Considerations in the Elderly Patient

Author： Bright David R. Calinski Diane M. Kisor David F.

Publisher： American Society of Consultant Pharmacists

ISSN： 0888-5109

Source： The Consultant Pharmacist, Vol.30, Iss.4, 2015-04, pp. : 228-239

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacogenetic considerations for acute lymphoblastic leukemia therapies

By Dulucq Stéphanie Laverdière Caroline Sinnett Daniel Krajinovic Maja

Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, Iss. 5, 2014-05 ,pp. : 699-719

Informa Healthcare

Access to resources Recommend Favorite

Anti-Parkinson's disease drugs and pharmacogenetic considerations

By Agúndez José A G

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 7, 2013-07 ,pp. : 859-874

Informa Healthcare

Access to resources Recommend Favorite

Pharmacogenetic considerations for non-Hodgkin's lymphoma therapy

By Espirito Santo Ana Medeiros Rui

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 12, 2013-12 ,pp. : 1625-1634

Informa Healthcare

Access to resources Recommend Favorite

Pharmacogenetic considerations for late life depression therapy

By Pitychoutis Pothitos M Kokras Nikolaos Sanoudou Despina Dalla Christina Papadopoulou-Daifoti Zeta

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 8, 2013-08 ,pp. : 989-999

Informa Healthcare

Access to resources Recommend Favorite

Fluoroquinolones in the Elderly: Safety Considerations

By Stahlmann R.

Drugs & Aging, Vol. 20, Iss. 4, 2003-01 ,pp. : 289-302

Adis International

Access to resources Recommend Favorite